Search

Displaying results 471 - 480 of 3917 in total
  1. Drug

    Agrostis gigantea pollen

    go.drugbank.com/drugs/DB10403
    Approved

    Agrostis gigantea pollen is the pollen of the Agrostis gigantea plant. Agrostis gigantea pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Standardized and Non-Standardized Inland Grasses, Mixture of Standardized and Non-Standardized Southern GrassesCategories: Non-Standardized Pollen Allergenic Extract
  2. Drug

    Elranatamab

    go.drugbank.com/drugs/DB15395
    ApprovedInvestigational

    [L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437] … [L47815] On August 14, 2023, the FDA granted accelerated approval to elranatamab for the treatment of multiple myeloma.

  3. Drug

    Technetium Tc-99m pertechnetate

    go.drugbank.com/drugs/DB09314
    ApprovedInvestigational

    However, in contrast to the iodide ion, the pertechnetate ion is released unchanged from the thyroid gland. … This is normally supplied in a hospital setting through the use of a technetium-99m generator, whereby technetium exits the generator in the form of the pertechnetate ion, TcO4−, which can be extracted

  4. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    on further verification in confirmatory trials. … Casimersen was granted accelerated FDA approval on February 25, 2021, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with casimersen; this approval is contingent

  5. Drug

    Benzydamine

    go.drugbank.com/drugs/DB09084
    ApprovedInvestigational

    Although the indazole analogue benzydamine is a non-steroidal anti-inflammatory drug (NSAID), it has various physicochemical properties and pharmacologic activities that are different from those of traditional

    Categories: Non COX-2 selective NSAIDS, Anti-Inflammatory Agents, Non-Steroidal
  6. Drug

    Tezacaftor

    go.drugbank.com/drugs/DB11712
    ApprovedInvestigational

    [L6814] This drug was approved by the FDA on February 12, 2018. … Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes.

  7. Drug

    Triticum aestivum pollen

    go.drugbank.com/drugs/DB10498
    Approved

    Triticum aestivum pollen is the pollen of the Triticum aestivum plant. Triticum aestivum pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Twenty-Two Standardized and Non-Standardized GrassesCategories: Non-Standardized Pollen Allergenic Extract
  8. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. … Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin

  9. Drug

    Brexucabtagene autoleucel

    go.drugbank.com/drugs/DB15699
    ApprovedInvestigational

    Mantle cell lymphoma (MCL) is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. … [L15148] Brexucabtagene autoleucel was granted full approval by the FDA on July 24, 2020 for the treatment of MCL and acute lymphoblastic leukemia (ALL), and is currently available through Kite Pharma

  10. Drug

    Magnesium sulfate

    go.drugbank.com/drugs/DB00653
    ApprovedInvestigationalVet approved

    A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and...

    Mixtures: ELETTROLITICA DI MANTENIMENTO CON GLUCOSIO FKI, ELETTROLITICA DI MANTENIMENTO CON GLUCOSIO FKI